- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immutep Ltd ADR (IMMP)
Immutep Ltd ADR stock price live, this page displays NASDAQ IMMP stock exchange data. View the IMMP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Immutep Ltd ADR real time stock price chart below.
What Is the Immutep Ltd ADR Stock Price Today?
The Immutep Ltd ADR stock price today is 1.760.
What Is the Stock Symbol for Immutep Ltd ADR?
The stock symbol for Immutep Ltd ADR is ""IMMP.""
What Stock Exchange Does Immutep Ltd ADR Trade On?
Immutep Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Immutep Ltd ADR a Good Stock to Buy?
Determining whether Immutep Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMMP quote. (ISIN: US45257L1089)
What Is the Immutep Ltd ADR Stock Price Today?
The Immutep Ltd ADR stock price today is 1.760.
What Is the Stock Symbol for Immutep Ltd ADR?
The stock symbol for Immutep Ltd ADR is ""IMMP.""
What Stock Exchange Does Immutep Ltd ADR Trade On?
Immutep Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Immutep Ltd ADR a Good Stock to Buy?
Determining whether Immutep Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMMP quote. (ISIN: US45257L1089)
1.760
-0.040(-2.21%)
Real-time Data·
Fair Value
An estimate of a Immutep ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.760
1.830
52 wk Range
1.320
2.720
IMMP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IMMP is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Immutep ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.7601.830
52 wk Range
1.3202.720
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMMP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Immutep ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
9.500
Upside
+439.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Immutep reports promising lung cancer trial results
- Investing.com
- Immutep shares new cancer study results
- Investing.com
- Immutep reports promising lung cancer trial results
- Investing.com
- Immutep stock soars on promising trial results
- Investing.com
- Immutep reports quarterly activities and financials
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Immutep Ltd ADR Company Profile
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Compare IMMP to Peers and Sector
Metrics to compare | IMMP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMMPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.0x | −3.2x | −0.5x | |
PEG Ratio | −0.61 | −0.02 | 0.00 | |
Price/Book | 2.3x | 2.8x | 2.6x | |
Price / LTM Sales | 81.2x | 12.1x | 3.2x | |
Upside (Analyst Target) | - | 360.9% | 41.2% | |
Fair Value Upside | Unlock | −1.1% | 6.2% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.500
(+439.77% Upside)
Earnings
Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Immutep ADR Trade On?
Immutep ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Immutep ADR?
The stock symbol for Immutep ADR is "IMMP."
What Is the Immutep ADR Market Cap?
As of today, Immutep ADR market cap is 258.60M.
What Is Immutep ADR's Earnings Per Share (TTM)?
The Immutep ADR EPS (TTM) is -0.03.
When Is the Next Immutep ADR Earnings Date?
Immutep ADR will release its next earnings report on 26 Aug 2025.
From a Technical Analysis Perspective, Is IMMP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Immutep ADR Stock Split?
Immutep ADR has split 1 times.
How Many Employees Does Immutep ADR Have?
Immutep ADR has 31 employees.
What is the current trading status of Immutep ADR (IMMP)?
As of 29 Jul 2025, Immutep ADR (IMMP) is trading at a price of 1.76, with a previous close of 1.80. The stock has fluctuated within a day range of 1.76 to 1.83, while its 52-week range spans from 1.32 to 2.72.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.